# Feasibility Assessment: NF-κB–Complement Cascade Hypotheses
---
## Hypothesis 1: Direct NF-κB Transcriptional Regulation of C1q Genes
### Druggability
**Moderate-High Technical Feasibility / Low Clinical Tractability**
- **IKKβ inhibitors** (ML120B, BAY 11-7082) exist but lack selectivity; broad NF-κB suppression causes immunosuppression and hepatotoxicity
- **REL-A/p65 inhibitors** are preclinical—no selective clinical-stage compounds exist
- **BET bromodomain inhibitors** (JQ1) indirectly suppress NF-κB-dependent transcription but have pleiotropic effects
- **Druggable target** exists but therapeutic index is narrow; systemically inhibiting NF-κB in microglia requires CNS-penetrant, cell-type-selective approaches not yet available
### Biomarkers/Model Systems
- **Biomarkers**: p65 nuclear translocation (flow cytometry of blood monocytes), C1QA/C1QB mRNA (qPCR), serum C1q protein (ELISA)
- **Model systems**: Primary murine microglia (4% sevoflurane, 2h), human iPSC-derived microglia, ChIP-seq for p65 occupancy
- **Gap**: Peripheral C1q does not reliably reflect brain complement activity; CSF sampling is invasive
### Clinical Development Constraints
- Demonstrating target engagement requires CNS penetration and microglial selectivity—currently intractable combination
- Phase I would need extensive neurocognitive testing even with clean safety signals
- Post-anesthesia neuroinflammation is acute and self-limited; trial design must capture narrow therapeutic window
### Safety
- NF-κB inhibition risks: impaired immune response to infection, impaired wound healing, hepatic toxicity, potential increase in neurodegeneration given NF-κB's neuroprotective roles
- Chronic administration is contraindicated; acute periprocedural use would require single-dose safety database
### Timeline/Cost
| Milestone | Timeline | Cost |
|-----------|----------|------|
| Target validation + ChIP-seq | 12–18 months | $300–500K |
| Lead optimization (selective IKKβ) | 24–36 months | $2–4M |
| IND-enabling studies | 18–24 months | $3–5M |
| Phase I safety (single-dose) | 12–18 months | $5–8M |
**Overall Assessment**: Mechanistically plausible but drug development is high-risk due to pleiotropic NF-κB biology. The skeptic is correct that promoter κB sites ≠ functional regulation. Confidence should remain at **0.45–0.55** pending direct ChIP data.
---
## Hypothesis 2: Astrocyte IL-1β as Paracrine Mediator
### Druggability
**High Clinical Tractability**
- **Anakinra** (IL-1RA): FDA-approved, safe, but poor CNS penetration (CSF:plasma ratio ~1:200)
- **Canakinumab**: Monoclonal antibody; cannot cross BBB; not suitable for direct CNS effect
- **LMW IL-1R antagonists** crossing BBB: Preclinical only (e.g., pyrin modulators)
- **Astrocyte-selective IL-1β blockade**: Requires cell-type targeting not currently feasible in clinic
### Biomarkers/Model Systems
- **Biomarkers**: CSF IL-1β (ultra-sensitive Simoa), microglial IL-1R1 expression (CX3CR1+/IL-1R1+ flow), C1q protein in hippocampal tissue
- **Model systems**: Astrocyte-microglia co-culture with transwell separation; GFAP-tdTomato mice for astrocyte-specific IL-1β measurement
- **Advantage**: IL-1β is quantifiable in patient CSF; correlates with neuroinflammation severity
### Clinical Development Constraints
- IL-1β is one of several redundant inflammatory signals; blocking it may not reduce C1q sufficiently
- BBB penetration of IL-1 inhibitors is